Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

ABSTRACT: RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tumor necrosis factor works in tumor tissue and healthy tissue. PURPOSE: This clinical trial is studying tumor necrosis factor in patients undergoing surgery for primary cancer or metastatic cancer .

DISEASE(S): Gastrointestinal Neoplasms,Carcinoma,Sarcoma,Melanoma,Adrenocortical Carcinoma,Colorectal Cancer,Gastrointestinal Cancer,Liver Cancer,Pancreatic Cancer,Liver Neoplasms,Breast Neoplasms,Breast Cancer,Ovarian Cancer,Melanoma (skin),Kidney Cancer,Pancreatic Neoplasms

PROVIDER: 2037202 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of human primary foreskin fibroblasts treated with tumor necrosis factor alpha

Project description:Treatment of primary human foreskin fibroblasts with tumor necrosis factor alpha

2009-09-01 | E-MEXP-2186 | biostudies-arrayexpress

Spleen vs Tumor necrosis factor-alpha Treated B cell

Project description:total RNA from mouse (male c57BL/6) spleen labeled with Cy3 vs total RNA from mouse (male c57BL/6) B cells treated with Tumor necrosis factor-alpha labeled with Cy5- time course with repeats Keywords: ordered

2003-04-14 | GSE401 | GEO

Tumor Necrosis Factor Associated Factor 2 Mediates Cardiac Protection Through Non-canonical NF-κB Signaling

Project description:Tumor Necrosis Factor Associated Factor 2 Mediates Cardiac Protection Through Non-canonical NF-κB Signaling

| PRJNA420992 | ENA

Targeted delivery of tumor necrosis factor in combination with lomustine induces a T-cell dependent regression of glioblastoma

Project description:Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies. Here we report that the combination of L19TNF, an antibody-cytokine fusion protein based on tumor necrosis factor that selectively localizes on the tumor neo-vasculature, with the alkylating agent lomustine, can induce tumor regression in orthotopic glioma-bearing mice and patients with recurrent glioblastoma. Mechanistically, this striking synergy crucially depended on T cells and involved activation of the tumor endothelium, tumor DNA damage, treatment-associated tumor necrosis, increased antigen presentation on MHC class I and tumor immune cell infiltration, as well as decreased tumor-associated immunosuppression. The clinical translation of this approach is ongoing, but already shows durable responses in the first recurrent glioblastoma patient cohort treated with L19TNF in combination with lomustine (NCT04573192).

2023-06-01 | PXD041256 | Pride

RNA-Seq analysis of colonic mesenchyme lacking tumor necrosis factor receptor 1

Project description:RNA-Seq analysis of colonic mesenchyme lacking tumor necrosis factor receptor 1

| PRJNA748108 | ENA

Single-cell analysis of colonic organoids deficient for tumor necrosis factor receptor 2

Project description:Single-cell analysis of colonic organoids deficient for tumor necrosis factor receptor 2

| PRJNA962604 | ENA

Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Inflammatory Bowel Disease

Project description:This will be a randomized placebo-controlled trial in inflammatory bowel disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity

| 2752894 | ecrin-mdr-crc

DNA methylation analysis of BeWo cells stimulated by tumor necrosis factor-alpha and insulin-like growth factor-I

Project description:DNA methylation analysis of BeWo cells stimulated by tumor necrosis factor-alpha and insulin-like growth factor-I

| PRJNA489857 | ENA

Gene expression analysis of BeWo cells stimulated by tumor necrosis factor-alpha and insulin-like growth factor-I

Project description:Gene expression analysis of BeWo cells stimulated by tumor necrosis factor-alpha and insulin-like growth factor-I

| PRJNA489858 | ENA

Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response

Project description:Background: The immunologic response to stress is regulated by the cytokines. Anti-Tumor Necrosis Factor-α agents are antibodies directed against a key cytokine in the process angiogenesis and collagen synthesis. It is not known whether they intervene with surgical stress response increasing the rate of postoperative complications. Method: Un-blinded prospective, non-interventional cohort single centre study including all the patients with Crohn’s disease and Ulcerative Colitis undergoing abdominal surgery. Immunological and endocrinological parameters will measured in blood samples taken from these patients before and after surgery. Power calculations showed that 17 patients in each arm are needed.

| 2154083 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data